Search

Search Constraints

You searched for: Subject 616.99481005

Search Results

2. 18F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling. Issue 2 (8th December 2019)

3. [18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab. Issue 3 (9th March 2022)

5. A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Issue 4 (19th November 2018)

9. A multidisciplinary neuro-oncological triage panel reduces the time to referral and treatment for patients with a brain tumor. Issue 5 (6th July 2021)

10. A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Issue 3 (31st January 2022)